Passage Bio, Inc.
Clinical-stage company developing one-time gene therapies for neurodegenerative diseases. The organization focuses on AAV-based gene delivery to the central nervous system, with clinical-stage programs to elevate progranulin for genetic forms of frontotemporal dementia. Activities described on company pages include preclinical development, early-phase multinational clinical trials, CMC analytics, scalable AAV manufacturing process development, regulatory interactions, and patient identification partnerships.
Industries
Nr. of Employees
medium (51-250)
Passage Bio, Inc.
1 Commerce Square, 2005 Market Street, 39th Floor, Philadelphia, PA 19103
Products
Clinical-stage AAV gene therapy candidate targeting progranulin deficiency
A clinical-stage AAV vector candidate designed to deliver a functional progranulin transgene to the CNS via a single intrathecal (cisterna magna) injection to elevate progranulin levels in patients with GRN-related frontotemporal dementia.
Clinical-stage AAV gene therapy candidate targeting progranulin deficiency
A clinical-stage AAV vector candidate designed to deliver a functional progranulin transgene to the CNS via a single intrathecal (cisterna magna) injection to elevate progranulin levels in patients with GRN-related frontotemporal dementia.
Services
Support for no-cost genetic testing and counseling programs to identify patients with genetic forms of CNS disease for clinical trial eligibility.
Support for no-cost genetic testing and counseling programs to identify patients with genetic forms of CNS disease for clinical trial eligibility.
Expertise Areas
- Gene therapy vector design
- AAV bioprocess scale-up and manufacturing
- CNS-targeted intrathecal delivery methods
- Early-phase clinical trial management
Key Technologies
- AAV-based gene delivery
- Intrathecal cisterna magna (ICM) administration
- Image-guided procedural delivery
- Suspension-based triple-transfection AAV manufacturing
News & Updates
Company presentation at an investor conference.
Poster describing transition from adherent to suspension-based triple-transfection for scalable AAV manufacturing.
Quarterly financial results and business update.
Interim clinical data and program updates for the upliFT-D study.
Peer-reviewed articles and conference posters on intrathecal AAV delivery, efficacy in preclinical models, and safety/toxicity investigations.
Company presentation at an investor conference.
Poster describing transition from adherent to suspension-based triple-transfection for scalable AAV manufacturing.
Quarterly financial results and business update.
Interim clinical data and program updates for the upliFT-D study.
Peer-reviewed articles and conference posters on intrathecal AAV delivery, efficacy in preclinical models, and safety/toxicity investigations.